Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?

WHO’s recommendation around a pre-vaccination screening strategy for Sanofi’s Dengvaxia could potentially dull the prospects of the product further, especially in emerging markets with stretched healthcare resources. One industry expert suggests that governments should probably consider introducing the vaccine only after “better tests and tools” become available.

Mosquito
SANOFI'S DENGUE VACCINE FACES MORE CHALLENGES

Sanofi’s dengue vaccine Dengvaxia’s checkered growth trajectory may be under further strain, with an expert group of the World Health Organization recommending a “pre-vaccination screening strategy” as the “preferred option” in countries evaluating vaccination as part of their dengue control program.

Only dengue-seropositive persons should be vaccinated under this plan, the Strategic Advisory Group of Experts (SAGE) on Immunization, the principal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip